Recent Updates
Recently added Catalysts

PF-08642534

Phase 1

Healthy Participant | Small molecule | Other |Pfizer, Inc.|Last Updated: Aug 21, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment14

FDA Designations

No designations recorded

Clinical trial landscape

PF-08642534 · 2 trials · 2 indications

Phase 1 2
NCT07731139A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have ObesityObesity
NOT YET_RECRUITING120 Analytics
NCT07575945A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.Healthy Participant
COMPLETED14 Analytics
PHASE1NOT YET_RECRUITING
A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity
Obesity
NCT07731139120
Unlock trial analytics
PHASE1COMPLETED
A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.
Healthy Participant
NCT0757594514
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of treatment emergent adverse events (TEAE)
Baseline up to 8 weeks after last dose
PF-08642534 Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
0 to 240 hours post-dose

Secondary Endpoints

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-08642534
0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of PF-08642534
0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose
Incidence of treatment-emergent Adverse Events
Baseline up to approximately 8 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
PlaceboEXPERIMENTALParticipants will receive matching placebo QD
PF-08642534EXPERIMENTALParticipants will receive PF-08642534 QD
Period 1--PF-08642534EXPERIMENTALParticipants will receive a single dose of PF-08642534
Period 2--itraconazole plus PF-08642534EXPERIMENTALParticipants will receive single doses of PF-08642534) in presence of itraconazole.

Interventions

NameTypeDescription
PF-08642534DRUGParticipants will receive PF-08642534 QD (once a day)
PlaceboDRUGParticipants will receive matching placebo QD (once a day)
ItraconazoleDRUGParticipants will receive itraconazole once daily for 13 days (Day 12 to Day 24)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion: * Body mass index (BMI) ≥30.0 and ≤40.0 kg/m², and with stable body weight prior to screening. * Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension) Exclusion: \- Individuals with diabetes, significant cardiovascular, hep...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

HIGHAug 21, 2026NCT07575945Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHAug 21, 2026NCT07575945Status: ACTIVE_NOT_RECRUITING → COMPLETED
LOWJul 28, 2026NCT07731139NEW_TRIAL: changed
LOWJul 28, 2026NCT07731139NEW_TRIAL: changed
MEDIUMJun 16, 2026NCT07575945Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMJun 16, 2026NCT07575945Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMJun 16, 2026NCT07575945Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMJun 16, 2026NCT07575945Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING

Frequently asked questions about PF-08642534

What is PF-08642534 used for?

PF-08642534 is an investigational small molecule being studied for obesity and in healthy participants. It is in Phase 1 clinical development, with trials evaluating how the body processes the drug and how different doses are tolerated and act in people with obesity.

Who makes PF-08642534?

PF-08642534 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE on the New York Stock Exchange. The company is conducting Phase 1 clinical trials of this investigational small molecule.

What phase is PF-08642534 in?

PF-08642534 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. Two Phase 1 trials are listed, one completed and one not yet recruiting, both in the United States.

What clinical trials is PF-08642534 in?

PF-08642534 has two Phase 1 trials. NCT07575945, completed, studied how itraconazole affects the body's processing of PF-08642534 in healthy adults. NCT07731139, not yet recruiting, is studying how different doses are tolerated and act in people with obesity.

Is PF-08642534 the same as itraconazole?

No, PF-08642534 is not the same as itraconazole. Itraconazole is a separate medicine used in a clinical trial to learn if it changes how the body processes PF-08642534 in healthy adults. PF-08642534 is the investigational study medicine.